Ozempic Blindness and Eye Risks: What the NAION Data Show
Ozempic blindness explained: what NAION studies found, what EU and U.S. labels say, the retinopathy warning and when vision changes are urgent.
Read MoreOzempic blindness explained: what NAION studies found, what EU and U.S. labels say, the retinopathy warning and when vision changes are urgent.
Read MoreZepbound sleep apnea facts: the December 2024 FDA approval, SURMOUNT-OSA results, why CPAP still matters and how other GLP-1 drugs compare.
Read MoreOzempic lawsuit facts from court records: the federal GLP-1 cases on gastroparesis and NAION, key rulings, what the labels say and status in 2026.
Read MoreTrulicity side effects from the March 2026 label: nausea and diarrhea rates versus placebo, the boxed warning, serious risks and weight change.
Read MoreStopping Ozempic: what withdrawal trials of semaglutide and tirzepatide found about weight regain, appetite and health markers, and why to plan first.
Read MoreOzempic heartburn explained: reflux and indigestion rates from four GLP-1 labels, why slower stomach emptying matters and when to get help.
Read MoreOzempic and pregnancy explained: when the labels say to stop, birth control on Zepbound, breastfeeding facts and what is known about Ozempic babies.
Read MoreOzempic thyroid cancer risk explained: what the boxed warning says, who should not use it, what human studies found and symptoms to report.
Read MoreWhat is food noise? The 2025 research definition, how common it is, what GLP-1 studies show and non-drug ways to quiet food noise.
Read MoreOzempic teeth explained: what GLP-1 labels say about dry mouth and taste changes, how vomiting affects enamel, and dentist-backed habits.
Read More